Loading
Osimertinib / Cisplatin or Carboplatin; Pemetrexed or Paclitaxel / Lung Cancer · Phase 2 Trial
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration evaluating osimertinib as induction therapy prior to concurrent chemoradiotherapy (CRT) followed by osimertinib maintenance in Stage III unresectable NSCLC with common EGFR mutations. The study is actively recruiting or recently closed to recruitment, but no results are posted in this registry record; the primary outcome is progression-free survival assessed up to approximately 4 years.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Lung Cancer; age from 18 Years; to 130 Years. Intervention: Open-Label Osimertinib Induction Treatment. n = 76. 39 sites across 9 countries.
This is a Phase 2 trial registration evaluating osimertinib as induction therapy prior to concurrent chemoradiotherapy (CRT) followed by osimertinib maintenance in Stage III unresectable NSCLC with common EGFR mutations. The study is actively recruiting or recently closed to recruitment, but no results are posted in this registry record; the primary outcome is progression-free survival assessed up to approximately 4 years.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Results are not yet available. When complete, this Phase 2 trial will inform whether osimertinib-based induction followed by chemoradiotherapy and maintenance therapy improves progression-free survival in this population, a question relevant to treatment sequencing in advanced EGFR-mutant NSCLC.
This is an active, ongoing Phase 2 trial registration with no results posted; the design and planned endpoints are reported but outcome data are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Results are not yet available. When complete, this Phase 2 trial will inform whether osimertinib-based induction followed by chemoradiotherapy and maintenance therapy improves progression-free survival in this population, a question relevant to treatment sequencing in advanced EGFR-mutant NSCLC.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06194448). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 76 participants (ACTUAL). Conditions: Lung Cancer. Interventions: DRUG: Osimertinib; DRUG: Cisplatin or Carboplatin; Pemetrexed or Paclitaxel; DRUG: Radiation. Primary outcome measures: PFS (Progression-Free Survival) , Assessed from date of first dose to progression (up to a maximum of approximately 4 years). Brief summary: The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.